Novo Nordisk

Novo Nordisk is a global healthcare company that discovers, develops, manufactures and delivers medicines for serious chronic diseases. Founded in 1923 and headquartered in Denmark, the company employs approximately 67,000 people, operates in 80 countries and serves more than 46.5 million people worldwide. Its therapeutic focus covers diabetes and obesity medicine, haemophilia, growth disorders and cardiovascular disease.

The company's operations span multiple jurisdictions. Production sites are located in Belgium, Brazil, China, Denmark, France, Italy and the United States, while research and development facilities sit in China, Denmark, India, the UK and the US. Affiliates are present across 80 countries. This footprint places the business within the pharmaceutical, healthcare, diabetes care, obesity care, haematology, endocrinology and cardiovascular industry sectors, all of which operate under national and supranational regulatory regimes.

Novo Nordisk describes its approach as integrated, spanning discovery through to delivery, and combines scientific research with attention to patients' circumstances. Its stated priorities include pioneering scientific breakthroughs and expanding global access to treatment. The company's history of more than a century frames its current scale and its presence across Europe, Asia and the Americas.